[1]
|
内科住院患者静脉血栓栓塞症预防中国专家建议(2015) [J]. 中华老年医学杂志, 2015, 34(4): 345-352.
|
[2]
|
Keramidas, G., Gourgoulianis, K.I. and Kotsiou, O.S. (2021) Venous Thromboembolic Disease in Chronic Inflammatory Lung Diseases: Knowns and Unknowns. Journal of Clinical Medicine, 10, Article No. 2061.
https://doi.org/10.3390/jcm10102061
|
[3]
|
Albertsen, I.E., Goldhaber, S.Z., Piazza, G., Overvad, T.F., Nielsen, P.B., Larsen, T.B., et al. (2020) Predictors of Not Initiating Anticoagulation After Incident Venous Thromboembolism: A Danish Nationwide Cohort Study. The American Journal of Medicine, 133, 463-472. https://doi.org/10.1016/j.amjmed.2019.08.051
|
[4]
|
Lee, L.H., Gallus, A., Jindal, R., Wang, C. and Wu, C.C. (2017) Incidence of Venous Thromboembolism in Asian Populations: A Systematic Review. Thrombosis and Haemostasis, 117, 2243-2260.
https://doi.org/10.1160/TH17-02-0134
|
[5]
|
Zhai, Z., Kan, Q., Li, W., Qin, X., Qu, J., Shi, Y., et al. (2019) VTE Risk Profiles and Prophylaxis in Medical and Surgical Inpatients: The Identification of Chinese Hospitalized Patients’ Risk Profile for Venous Thromboembolism (DissolVE-2)—A Cross-sectional Study. Chest, 155, 114-122. https://doi.org/10.1016/j.chest.2018.09.020
|
[6]
|
马萍. 内科住院病人VTE风险评估及预防研究进展[J]. 全科护理, 2021, 19(32): 4496-4499.
|
[7]
|
《中国血栓性疾病防治指南》专家委员会. 中国血栓性疾病防治指南[J]. 中华医学杂志, 2018, 98(36): 2861-2888.
|
[8]
|
Flevas, D.A., Megaloikonomos, P.D., Dimopoulos, L., Mitsiokapa, E., Koulouvaris, P. and Mavrogenis, A.F. (2018) Thromboembolism Prophylaxis in Orthopaedics: An Update. EFORT Open Reviews, 3, 136-148.
https://doi.org/10.1302/2058-5241.3.170018
|
[9]
|
Alsheikh, K., Hilabi, A., Aleid, A., Alharbi, K.G., Alangari, H.S., Alkhamis, M., et al. (2021) Efficacy and Safety of Thromboprophylaxis Post-Orthopedic Surgery. Cureus, 13, Article ID: e19691. https://doi.org/10.7759/cureus.19691
|
[10]
|
Bundhun, P.K., Shaik, M. and Yuan, J. (2017) Choosing between Enoxaparin and Fondaparinux for the Management of Patients with Acute Coronary Syndrome: A Systematic Review and Meta-Analysis. BMC Cardiovascular Disorders, 17, Article No. 116. https://doi.org/10.1186/s12872-017-0552-z
|
[11]
|
Prandoni, P., Cattelan, A.M., Carrozzi, L., Leone, L., Filippi, L., De Gaudenzi, E., et al. (2020) The Hazard of Fondaparinux in Non-Critically Ill Patients with COVID-19: Retrospective Controlled Study versus Enoxaparin. Thrombosis Research, 196, 395-397. https://doi.org/10.1016/j.thromres.2020.09.024
|
[12]
|
李天华, 李春柳, 耿倩, 丁俊琴. 静脉血栓栓塞症风险评估工具的研究进展[J]. 中华现代护理杂志, 2019, 25(35): 4657-4661.
|
[13]
|
Golemi, I., Salazar Adum, J.P., Tafur, A. and Caprini, J. (2019) Venous Thromboembolism Prophylaxis Using the Caprini Score. Disease-a-Month, 65, 249-298. https://doi.org/10.1016/j.disamonth.2018.12.005
|
[14]
|
王辰, 刘常清, 安晶晶, 谭永琼, 廖安鹊, 罗艳丽. 静脉血栓栓塞症风险评估工具研究进展[J]. 护理研究, 2020, 34(23): 4211-4217.
|
[15]
|
Frederiksen, J., Juul, K., Grande, P., Jensen, G.B., Jensen, G.B., Schroeder, T.V., Tybjaerg-Hansen, A., et al. (2004) Methylenetetrahyd rofolate Reduc-tase Polymorphism (C677T), Hyperhomocysteinemia, and Risk of Ischemic Cardiovascular Disease and Venous Thromboembolism: Prospective and Case-Control Studies from the Copenhagen City Heart Study. Blood, 104, 3046-3051. https://doi.org/10.1182/blood-2004-03-0897
|
[16]
|
McColl, M.D., Sattar, N., Ellison, J., Tait, R.C., Walker, I.D., Packard, C.J., et al. (2000) Lipoprotein (a), Cholesterol and Triglycerides in Women with Venous Throm-boembolism. Blood Coagulation & Fibrinolysis, 11, 225-229.
|
[17]
|
Seguí, R., Estellés, A., Mira, Y., España, F., Villa, P., Falcó, C., et al. (2000) PAI-1 Promoter 4G/5G Genotype as an Additional Risk Actor or Venous Thrombosis in Subjects with Genetic Thrombophilic Defects. British Journal of Haematology, 111, 122-128. https://doi.org/10.1111/j.1365-2141.2000.02321.x
|
[18]
|
Zamani, A., Omrani, G.R. and Lankarani, K.B. (2003) Hy-perhomocysteinaemia, Hyperlipidaemia and Risk of Venous Thromboembolism in Shiraz. Eastern Mediterranean Health Journal, 9, 935-943.
https://doi.org/10.26719/2003.9.5-6.935
|
[19]
|
Ageno, W., Becattini, C., Brighton, T., Selby, R. and Kamphuisen, P.W. (2008) Cardiovascular Risk Factors and Venous Thromboembolism: A Meta-Analysis. Circulation, 117, 93-102.
https://doi.org/10.1161/CIRCULATIONAHA.107.709204
|
[20]
|
Everett, B.M., Glynn, R.J., Buring, J.E. and Ridker, P.M. (2009) Lipid Biomarkers, Hormone Therapy and the Risk of Venous Thromboembolism in Women. Jour-nal of Thrombosis and Haemostasis, 7, 588-596.
https://doi.org/10.1111/j.1538-7836.2009.03302.x
|
[21]
|
Delluc, A., Malécot, J.M., Kerspern, H., Nowak, E., Carre, J.L., Mottier, D., et al. (2012) Lipid Parameters, Lipid Lowering Drugs and the Risk of Venous Thromboembolism. Ath-erosclerosis, 220, 184-188.
https://doi.org/10.1016/j.atherosclerosis.2011.10.007
|
[22]
|
Gregson, J., Kaptoge, S., Bolton, T., Pennells, L., Willeit, P., Burgess, S., et al. (2019) Cardiovascular Risk Factors Associated with Venous Thromboembolism. JAMA Cardiolo-gy, 4, 163-173.
https://doi.org/10.1001/jamacardio.2018.4537
|
[23]
|
刘祝. 深静脉血栓形成合并肺栓塞患者危险因素分析[D]: [硕士学位论文]. 天津: 天津医科大学, 2020.
|
[24]
|
李婉影, 刘会, 高清平. 出凝血分子标志物对脓毒血症合并弥散性血管内凝血的早期诊断和预后评估的价值[J]. 内科急危重症杂志, 2019, 25(1): 31-34.
|
[25]
|
Falck-Ytter, Y., Francis, C.W., Johanson, N.A., Curley, C., Dahl, O.E., Schulman, S., et al. (2012) Prevention of VTE in Orthopedic Surgery Patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 14, e278S-e325S.
https://doi.org/10.1378/chest.11-2404
|
[26]
|
Kolluri, R., Plessa, A.L., Sanders, M.C., Singh, N.K. and Lucore, C. (2016) A Randomized Study of the Safety and Efficacy of Fondaparinux versus Placebo in the Prevention of Venous Thromboembolism after Coronary Artery Bypass Graft Surgery. American Heart Journal, 171, 1-6. https://doi.org/10.1016/j.ahj.2015.10.013
|
[27]
|
Kahale, L.A., Matar, C.F., Hakoum, M.B., Tsolakian, I.G., Yosuico, V.E., Terrenato, I., et al. (2021) Anticoagulation for the Initial Treatment of Venous Thromboembolism in People with Cancer. Cochrane Database of Systematic Reviews, No. 12, Article No. 12, CD006649. https://doi.org/10.1002/14651858.CD006649.pub8
|
[28]
|
Russo, V., Cardillo, G., Viggiano, G.V., Mangiacapra, S., Cavalli, A., Fontanella, A., et al. (2020) Fondaparinux Use in Patients with COVID-19: A Preliminary Multicenter Re-al-World Experience. Journal of Cardiovascular Pharmacology, 76, 369-371. https://doi.org/10.1097/FJC.0000000000000893
|
[29]
|
Bachler, M., Niederwanger, C., Hell, T., Höfer, J., Gerst-meyr, D., Schenk, B., et al. (2019) Influence of Factor XII Deficiency on Activated Partial Thromboplastin Time (aPTT) in Critically ill Patients. Journal of Thrombosis and Thrombolysis, 48, 466-474. https://doi.org/10.1007/s11239-019-01879-w
|